0JYO.LSE BB Biotech AG
- Market cap
- GBP 4.63B
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 5.33%
- Fundamental score
- -
Is 0JYO.LSE undervalued?
Graham numberThe Graham number of BB Biotech AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BB Biotech AG fundamental analysis
No fundamental analysis for BB Biotech AG yet.
BB Biotech AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
Full company profileFinancial statements of BB Biotech AG are not available yet.
BB Biotech AG dividends
BB Biotech AG has not paid dividends in the last 4 fiscal years.
Last stock split: 5:1 on Mar 29, 2016.
Who owns BB Biotech AG
- Insiders 0.08%
- Institutions 20.66%
- Public & others 79.27%
- Shares outstanding 55.4M
BB Biotech AG company profile
- Company name
- BB Biotech AG
- Ticker
- 0JYO.LSE
- ISIN
- CH0038389992
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- Seestrasse 16, Küsnacht, Switzerland, CH-8700
- Phone
- 41 44 2676700
- Website
- bbbiotech.ch/en/bb-biotech
About BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
BB Biotech AG management
1- Dr. Daniel Koller Ph.D.Head of Biotech, Portfolio Manager and Member of Executive Board · born 1970